These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22496772)

  • 1. Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses.
    Bruder JT; Semenova E; Chen P; Limbach K; Patterson NB; Stefaniak ME; Konovalova S; Thomas C; Hamilton M; King CR; Richie TL; Doolan DL
    PLoS One; 2012; 7(4):e33920. PubMed ID: 22496772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors.
    Bruder JT; Chen P; Semenova E; Thomas CA; Konovalova S; Ekberg G; Ettyreddy D; McVey D; Gall JG; King CR; Brough DE
    J Virol; 2013 Sep; 87(17):9661-71. PubMed ID: 23824800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
    Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
    Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.
    Sumida SM; Truitt DM; Lemckert AA; Vogels R; Custers JH; Addo MM; Lockman S; Peter T; Peyerl FW; Kishko MG; Jackson SS; Gorgone DA; Lifton MA; Essex M; Walker BD; Goudsmit J; Havenga MJ; Barouch DH
    J Immunol; 2005 Jun; 174(11):7179-85. PubMed ID: 15905562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectors.
    Teigler JE; Penaloza-MacMaster P; Obeng R; Provine NM; Larocca RA; Borducchi EN; Barouch DH
    Clin Vaccine Immunol; 2014 Aug; 21(8):1137-44. PubMed ID: 24943382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.
    Cheng C; Wang L; Gall JG; Nason M; Schwartz RM; McElrath MJ; DeRosa SC; Hural J; Corey L; Buchbinder SP; Nabel GJ
    PLoS One; 2012; 7(4):e33969. PubMed ID: 22496775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine.
    Fonseca JA; Cabrera-Mora M; Kashentseva EA; Villegas JP; Fernandez A; Van Pelt A; Dmitriev IP; Curiel DT; Moreno A
    PLoS One; 2016; 11(4):e0154819. PubMed ID: 27128437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5.
    Abe S; Okuda K; Ura T; Kondo A; Yoshida A; Yoshizaki S; Mizuguchi H; Klinman D; Shimada M
    J Gene Med; 2009 Jul; 11(7):570-9. PubMed ID: 19391169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilizing the antigen capsid-incorporation strategy for the development of adenovirus serotype 5-vectored vaccine approaches.
    Gu L; Farrow AL; Krendelchtchikov A; Matthews QL
    J Vis Exp; 2015 May; (99):e52655. PubMed ID: 25993057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.
    Bradley RR; Maxfield LF; Lynch DM; Iampietro MJ; Borducchi EN; Barouch DH
    J Virol; 2012 Jan; 86(2):1267-72. PubMed ID: 22072746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction and characterization of a recombinant human adenovirus type 3 vector containing two foreign neutralizing epitopes in hexon.
    Xue C; Tian X; Li X; Zhou Z; Su X; Zhou R
    Virus Res; 2014 Apr; 183():67-74. PubMed ID: 24518297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection.
    Bradley RR; Lynch DM; Iampietro MJ; Borducchi EN; Barouch DH
    J Virol; 2012 Jan; 86(1):625-9. PubMed ID: 22072776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.
    Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Gayle RB; Amalfitano A; Jones FR
    Immunol Lett; 2009 Jan; 122(1):44-51. PubMed ID: 19073216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model.
    Limbach K; Stefaniak M; Chen P; Patterson NB; Liao G; Weng S; Krepkiy S; Ekberg G; Torano H; Ettyreddy D; Gowda K; Sonawane S; Belmonte A; Abot E; Sedegah M; Hollingdale MR; Moormann A; Vulule J; Villasante E; Richie TL; Brough DE; Bruder JT
    Malar J; 2017 Jul; 16(1):263. PubMed ID: 28673287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity.
    Thorner AR; Lemckert AA; Goudsmit J; Lynch DM; Ewald BA; Denholtz M; Havenga MJ; Barouch DH
    J Virol; 2006 Dec; 80(24):12009-16. PubMed ID: 17035318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.
    Chmielewska AM; Naddeo M; Capone S; Ammendola V; Hu K; Meredith L; Verhoye L; Rychlowska M; Rappuoli R; Ulmer JB; Colloca S; Nicosia A; Cortese R; Leroux-Roels G; Balfe P; Bienkowska-Szewczyk K; Meuleman P; McKeating JA; Folgori A
    J Virol; 2014 May; 88(10):5502-10. PubMed ID: 24599994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
    Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
    Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The VP1 G-H loop hypervariable epitope contributes to protective immunity against Foot and Mouth Disease Virus in swine.
    Fernandez-Sainz I; Gavitt TD; Koster M; Ramirez-Medina E; Rodriguez YY; Wu P; Silbart LK; de Los Santos T; Szczepanek SM
    Vaccine; 2019 Jun; 37(26):3435-3442. PubMed ID: 31085001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.
    Morse MA; Chaudhry A; Gabitzsch ES; Hobeika AC; Osada T; Clay TM; Amalfitano A; Burnett BK; Devi GR; Hsu DS; Xu Y; Balcaitis S; Dua R; Nguyen S; Balint JP; Jones FR; Lyerly HK
    Cancer Immunol Immunother; 2013 Aug; 62(8):1293-301. PubMed ID: 23624851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon.
    Tian X; Su X; Li X; Li H; Li T; Zhou Z; Zhong T; Zhou R
    PLoS One; 2012; 7(7):e41381. PubMed ID: 22848478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.